GlassScriptPhysician profile
Jashan Gill
NPI 1447866579
$3,128.86
in general payments reported to CMS, 2019-2025
21 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $417 · 2024: $1,361 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Travel and Lodging: $320 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.36 |
| Travel and Lodging | $319.55 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $809.12 | 2023-2025 | Lifevest |
| Medtronic, INC. | $407.55 | 2024 | Onyx Frontier, Ffrangio |
| Astrazeneca Pharmaceuticals LP | $343.72 | 2023-2025 | Farxiga, Wainua, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $338.51 | 2024-2025 | Camzyos, Eliquis |
| Abiomed | $218.03 | 2023-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.22 | 2024-2025 | Jardiance |
| Biosense Webster, INC. | $168.60 | 2025 | Qdot Micro, Carto 3 |
| Boston Scientific Corporation | $158.44 | 2024-2025 | Farapulse |
| Novartis Pharmaceuticals Corporation | $88.09 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $78.85 | 2024 | Xarelto |
| Novo Nordisk INC | $50.40 | 2025 | Ozempic |
| Getinge USA Sales, LLC | $47.70 | 2024-2025 | Cardiosave Rescue, Cardiohelp |
| Alnylam Pharmaceuticals INC. | $47.14 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $32.80 | 2023-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $30.89 | 2023 | Opsumit, Uptravi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.50 | 2025 | |
| Merck Sharp & Dohme LLC | $20.56 | 2025 | Verquvo |
| Bridgebio Pharma, INC. | $16.78 | 2025 | Attruby |
| Convatec INC. | $14.47 | 2025 | |
| Terumo Medical Corporation | $13.83 | 2023 | Angio-Seal |
| Teleflex LLC | $13.66 | 2025 | Guideliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jashan Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.